Cart
sales@molnova.com
GSK2008607
CAS No. 1244644-50-5
GSK2008607( —— )
Catalog No. M34270 CAS No. 1244644-50-5
GSK2008607 is a potent B-RafV600E inhibitor with anticancer activity and can be used to study breast, colorectal, melanoma, thyroid, and ovarian cancers.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 532 | Get Quote |
|
| 5MG | 787 | Get Quote |
|
| 10MG | 1074 | Get Quote |
|
| 25MG | 1463 | Get Quote |
|
| 50MG | 1822 | Get Quote |
|
| 100MG | 2250 | Get Quote |
|
| 500MG | 4410 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameGSK2008607
-
NoteResearch use only, not for human use.
-
Brief DescriptionGSK2008607 is a potent B-RafV600E inhibitor with anticancer activity and can be used to study breast, colorectal, melanoma, thyroid, and ovarian cancers.
-
DescriptionGSK2008607 is a potent B-RafV600E inhibitor with anticancer activity and can be used to study breast, colorectal, melanoma, thyroid, and ovarian cancers.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMAPK/ERK Signaling
-
TargetRaf
-
RecptorRaf
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1244644-50-5
-
Formula Weight667.72
-
Molecular FormulaC31H28F3N7O3S2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC(C)(C)C=1SC(=C(N1)C2=C(F)C(NS(=O)(=O)C3=C(F)C=CC=C3F)=CC=C2)C4=NC(NC=5C=CC(=NC5)N6CCOCC6)=NC=C4
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Kobe2602
kobe2602 is a novel and effective small-molecule compound inhibiting Ras–Raf interaction by SBDD.
-
B-Raf IN 15
B-Raf IN 15 is a BRAF inhibitor that inhibits BRAFWT and BRAFV600E and can be used in the study of melanoma and cancer, and can be optimized for use as a more effective BRA F inhibitor.
-
Sorafenib-d3
Sorafenib-d3 is a deuterium-labeled Sorafenib which is a multikinase inhibitor(IC50s: 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively).
